Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges

Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges

The earnings call discussed steps for FDA approval of the A GE one cell line, timeline for trial results, and regulatory progress for the OX vaccine. FDA approval process for A GE one cell line is estimated at 18 months, with expedited options.

Read More

Did you find this insightful?